✅ Medically reviewed by Dr. Tom Biernacki, DPM, FACFAS
Board-certified podiatric surgeon · 3,000+ procedures · The Private Practice
Last reviewed: May 18, 2026
Quick answer: NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential to cellular energy production, DNA repair, and longevity signaling. It declines ~50% between ages 20 and 50. NMN and NR are precursors that raise NAD+ levels — but the human evidence on longevity outcomes is still emerging, and not all supplements are created equal.
In this article: What NAD+ Is · Why It Declines With Age · NAD+ and Sirtuins · NMN vs. NR · What the Human Evidence Shows · Dosing Protocol · Lifestyle vs. Supplements · FAQ · Bottom Line
I’ll be direct about where I stand on NAD+ precursors: the animal data is compelling. The human data is promising but preliminary. I take NMN myself — and I hold that position loosely, because the science hasn’t delivered the long-term randomized human trials we’d need to be confident about longevity outcomes specifically. What is not debatable: NAD+ is fundamental to cellular function, it declines substantially with age, and raising it has measurable effects on metabolic markers and cellular health in human trials. Whether that translates to longer life is still being studied. This is my honest read of where the evidence sits right now.
What NAD+ Is and Why It Matters
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of the body. It exists in two forms: the oxidized form (NAD+) and the reduced form (NADH). This NAD+/NADH cycling is the backbone of cellular energy metabolism — it’s the electron carrier that shuttles energy through the mitochondrial electron transport chain to produce ATP. Without NAD+, cells cannot generate energy. Every time you breathe, your mitochondria are cycling NAD+ and NADH thousands of times per second.
But NAD+’s role extends well beyond energy metabolism. It is the required substrate for three critical classes of enzymes:
Sirtuins (SIRT1–SIRT7): A family of NAD+-dependent deacetylases that regulate gene expression, DNA repair, inflammation, mitochondrial biogenesis, and cellular stress responses. Sirtuins are sometimes called “longevity genes” — they’re the proteins that caloric restriction and exercise activate, and their activity depends entirely on NAD+ availability.
PARPs (Poly ADP-Ribose Polymerases): DNA repair enzymes that consume NAD+ to fix strand breaks and other DNA damage. As we age and accumulate more DNA damage (from oxidative stress, UV radiation, inflammation), PARP activity increases — consuming NAD+ at accelerating rates. This creates a vicious cycle: more damage → more PARP activation → less NAD+ → less sirtuin activity → less repair capacity.
CD38: An NAD+ hydrolase enzyme whose expression increases with age and inflammation. CD38 consumes NAD+ — and its age-related increase is one of the primary drivers of the NAD+ decline seen with aging. Importantly, CD38 is activated by inflammatory signals — chronic low-grade inflammation accelerates NAD+ depletion through this pathway.
🔑 Key Takeaway
NAD+ is consumed by three competing processes: energy metabolism, DNA repair (PARPs), and inflammation (CD38). As aging increases DNA damage and inflammatory load simultaneously, NAD+ is depleted faster than it can be synthesized. The result is less fuel for the sirtuins that regulate cellular health and longevity.
Why NAD+ Declines With Age
NAD+ levels decline approximately 50% between ages 20 and 50, and continue falling thereafter. This is not primarily due to reduced synthesis — it’s driven by increased consumption. The three main mechanisms:
Increased PARP activity: DNA damage accumulates with age from oxidative stress, metabolic byproducts, and environmental exposures. Each repair event consumes NAD+. Older cells face more damage and mount more repair responses, consuming NAD+ at higher rates.
CD38 upregulation: CD38 expression increases substantially with age, particularly in immune cells and adipose tissue. Senescent cells — the dysfunctional “zombie cells” that accumulate with aging — are major sources of inflammatory cytokines that drive CD38 expression. This creates a feedback loop: senescence → inflammation → CD38 → NAD+ depletion → impaired sirtuin function → more cellular dysfunction → more senescence.
Reduced NAMPT expression: NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the salvage pathway — the primary route by which cells recycle NAD+ precursors back into NAD+. NAMPT expression declines with age, reducing the body’s capacity to regenerate NAD+ from its breakdown products. Exercise robustly upregulates NAMPT — another mechanism by which physical activity supports cellular longevity.
NAD+ and the Sirtuins: The Longevity Connection
Sirtuins are a family of seven proteins (SIRT1–SIRT7) that function as NAD+-dependent deacetylases — enzymes that remove acetyl groups from proteins, modifying their activity. They’re often called “longevity proteins” because of their central role in the biological processes associated with healthy aging: DNA repair, inflammation control, mitochondrial biogenesis, circadian rhythm regulation, and cellular stress responses.
SIRT1 is the most studied and activates many of the same pathways as caloric restriction — including AMPK signaling, mitochondrial biogenesis through PGC-1α, and reduced NF-κB (inflammatory) signaling. SIRT3 regulates mitochondrial function and reduces oxidative stress. SIRT6 is critical for DNA repair and telomere maintenance — mice overexpressing SIRT6 live significantly longer. The common thread: all seven sirtuins require NAD+ to function. As NAD+ levels fall with age, sirtuin activity decreases proportionally — reducing the cell’s capacity for self-maintenance.
David Sinclair at Harvard has been the most prominent voice arguing that declining NAD+ and sirtuin activity is a primary driver of aging itself — the “Information Theory of Aging” — rather than merely a consequence. This remains a hypothesis, not settled science. But the mechanistic case is strong enough that it has driven significant research investment into NAD+ precursor supplementation.
NMN vs. NR: Which NAD+ Precursor Is Better?
Two NAD+ precursors have received the most research attention: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are forms of vitamin B3 that enter the NAD+ biosynthesis pathway at different points and raise cellular NAD+ levels. The debate over which is superior is ongoing — and the honest answer is that the human data doesn’t definitively favor one over the other.
NR (Nicotinamide Riboside): The first NAD+ precursor to have published human clinical trial data. Multiple studies confirm that oral NR supplementation raises blood NAD+ levels in humans. It’s converted to NMN intracellularly before entering NAD+ synthesis. ChromaDex’s Tru Niagen is the most studied commercial NR product. NR has a longer safety record in human trials — studies up to 8 weeks have shown it to be well-tolerated.
NMN (Nicotinamide Mononucleotide): One step closer to NAD+ in the biosynthesis pathway. For years, a scientific debate existed about whether NMN could even cross the cell membrane directly — this was resolved when the transporter Slc12a8 was identified. Human trials of NMN (beginning with the Yoshino et al. 2021 study showing improved muscle insulin sensitivity in postmenopausal women on 250 mg/day) are now accumulating. NMN is more expensive than NR and has slightly less human safety data, but the mechanistic case for direct cellular uptake is now stronger.
Practical difference: Both raise blood NAD+ levels. NR has more human trial data overall. NMN may have advantages in specific tissues (particularly muscle and the gut). Some researchers argue the sublingual NMN formulation bypasses first-pass metabolism more efficiently. In practice, both are reasonable choices. I personally use NMN — but acknowledge that NR’s longer human trial track record is a reasonable argument in its favor.
🔑 Key Takeaway
NMN and NR both raise NAD+ levels in humans. NR has more published clinical trial data. NMN is one enzymatic step closer to NAD+ and has growing evidence. Neither has demonstrated longevity extension in humans — that data doesn’t exist yet. Both are safe at studied doses.
What the Human Evidence Actually Shows
Here’s where intellectual honesty requires slowing down. The animal evidence — particularly in mice — is remarkable: NMN and NR supplementation improves muscle function, cognitive performance, metabolic health, cardiovascular function, and even extends lifespan in aged mice. But mice are not humans, and rodent longevity studies have repeatedly failed to translate to humans in the history of aging research.
The human data to date shows:
NAD+ levels reliably increase: Multiple well-designed studies confirm that both NR and NMN supplementation raises blood NAD+ levels in humans — typically 1.5- to 2.5-fold. This is consistent and reproducible.
Metabolic improvements: The Yoshino et al. 2021 RCT found NMN improved skeletal muscle insulin sensitivity and expression of genes related to muscle remodeling in postmenopausal women with prediabetes. Other studies show improvements in aerobic capacity, blood pressure, and inflammatory markers.
Muscle and physical performance: A 2022 study in recreational runners showed NMN improved aerobic capacity and muscle oxygen utilization. A Japanese study of older adults showed improved gait speed and grip strength with NMN supplementation.
What we don’t yet have: Long-term randomized controlled trials showing reduced mortality, reduced disease incidence, or measurable lifespan extension in humans. The trials that exist are short (weeks to months), use biomarker endpoints, and have relatively small sample sizes. The longevity claims made by some supplement companies go well beyond what the current human evidence supports.
⚠️ Important Note
Resveratrol — the sirtuin activator that preceded the NAD+ precursor era in longevity supplement interest — also had compelling animal data that largely failed to translate to meaningful human longevity outcomes in well-designed trials. NAD+ precursors may have a different outcome, but intellectual honesty requires acknowledging this precedent. The mechanism is more direct; the uncertainty remains real.
Dosing Protocol and Practical Considerations
Based on the human trials to date, the evidence-based dosing range is:
NMN: 250–500 mg/day orally, or 125–250 mg sublingual. The Yoshino et al. study used 250 mg/day. Higher doses (500–1000 mg/day) are used in some trials without significant adverse effects. The sublingual formulation bypasses first-pass hepatic metabolism and may achieve higher plasma levels at lower doses.
NR: 250–500 mg/day. The original Trammell et al. study used 100–300 mg/day. ChromaDex’s Tru Niagen has been studied at 300 mg/day.
Timing: Morning dosing is generally recommended — NAD+ signaling interacts with circadian rhythm regulators, and morning dosing aligns with the body’s natural NAD+ cycling. Taking it with food may reduce mild GI discomfort some people experience initially.
Stacking considerations: NAD+ precursors are commonly combined with apigenin or quercetin (CD38 inhibitors — reducing NAD+ consumption), and with resveratrol (sirtuin activator — amplifying the downstream effect of raised NAD+). Whether this stack produces synergistic outcomes beyond individual components is not yet established in humans, but the mechanistic rationale is coherent.
Lifestyle Interventions That Raise NAD+
Before considering supplements, it’s worth noting that several lifestyle interventions measurably raise NAD+ levels or protect against its decline — and have the added benefit of proven outcomes across multiple health dimensions:
Exercise: Both aerobic exercise and resistance training upregulate NAMPT (the rate-limiting enzyme in NAD+ synthesis) and activate SIRT1. Zone 2 training in particular activates the same AMPK-sirtuin-mitochondrial axis that NAD+ supplementation targets. See: Zone 2 Training and Longevity.
Caloric restriction and fasting: Reducing caloric intake raises the NAD+/NADH ratio by decreasing the electron flux through the mitochondrial electron transport chain, shifting the balance toward the oxidized form. Intermittent fasting produces similar effects. See: Intermittent Fasting: What the Science Actually Shows.
Heat exposure (sauna): Repeated sauna use activates heat shock proteins and AMPK signaling, raising NAMPT expression. Regular sauna use is associated with significant reductions in cardiovascular mortality in observational studies, potentially through overlapping pathways with NAD+ biology.
Sleep: NAD+ levels cycle with circadian rhythm — disrupted sleep and circadian misalignment reduce NAD+ in critical tissues. Protecting sleep quality is a foundational NAD+ optimization strategy. See: Sleep Deprivation and Health.
Frequently Asked Questions
Is NMN or NR safe to take long-term?
Both have good short-term safety data in humans — studies up to several months show them to be well-tolerated at standard doses with no significant adverse effects. Long-term safety data beyond 1–2 years in humans is limited simply because the research is relatively new. One theoretical concern that has been raised: NAD+ precursors raise NAD+ in all cells, including potentially cancerous ones — though this concern has not been borne out in the human trial data to date, and most researchers consider the anti-inflammatory and DNA-repair-supporting effects of higher NAD+ to be net cancer-protective. As with all supplements, discuss with your physician if you have active cancer or a significant cancer history.
Should I take NMN/NR if I’m under 40?
The human evidence for meaningful NAD+ decline and supplementation benefit is strongest in people over 40–50, where the physiological decline is significant. Under 40, baseline NAD+ levels are typically adequate, and lifestyle interventions (exercise, sleep, fasting) are both effective and sufficient for supporting NAD+ metabolism. The cost-benefit of supplementation under 40 is less clear. That said, if you’re already optimizing diet, sleep, exercise, and stress — and want to add a precursor — the safety profile is acceptable. I wouldn’t prioritize it under 40 over lifestyle fundamentals.
Does NAD+ supplementation actually extend human lifespan?
We don’t know yet — and anyone who tells you definitively that it does or doesn’t is overreaching the evidence. What we know: NAD+ precursors raise NAD+ levels in humans, activate sirtuin signaling, improve metabolic markers, and replicate some of the cellular effects seen with caloric restriction and exercise in animal models. Whether this translates to measurable lifespan extension in humans requires decade-long prospective trials that haven’t been done. The honest position is: promising mechanism, good biomarker data, longevity outcomes in humans unknown.
Can I raise NAD+ through food?
Dietary NAD+ precursors contribute to total NAD+ synthesis — foods rich in niacin (vitamin B3), nicotinamide, and tryptophan (which can be converted to NAD+ via the de novo synthesis pathway) support NAD+ production. Rich dietary sources include: beef liver, chicken, tuna, salmon, edamame, and mushrooms (particularly white and cremini mushrooms contain meaningful amounts of NR). However, dietary sources alone are unlikely to significantly raise NAD+ levels in the context of age-related decline — supplemental doses of NMN or NR used in clinical trials are 100–500x the amounts obtainable from food. Diet supports baseline, supplements are what moves the needle on NAD+ blood levels.
The Bottom Line
NAD+ is genuinely central to cellular longevity biology — not a marketing concept. It declines substantially with age through mechanisms we understand: increased PARP and CD38 consumption, reduced NAMPT synthesis capacity. NMN and NR reliably raise blood NAD+ levels in humans and produce meaningful improvements in metabolic and muscle health markers in the trials completed to date. The honest caveat: longevity extension in humans is unproven. What is proven: the lifestyle interventions that raise NAD+ naturally — Zone 2 exercise, fasting, sleep optimization, stress management — have decades of longevity data behind them and should come first. If you’ve built that foundation and want to add an NAD+ precursor, the risk-benefit ratio is favorable. But supplements don’t substitute for the biology that the lifestyle interventions drive.
Sources
1. Yoshino M, et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science. 2021. PubMed
2. Trammell SA, et al. “Nicotinamide riboside is uniquely and orally bioavailable in healthy humans.” Nature Communications. 2016. PubMed
3. Shade C. “The Science Behind NMN–A Stable, Reliable NAD+Activator and Anti-Aging Molecule.” Integrative Medicine. 2020. PubMed
4. Zhu XH, et al. “In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences.” PNAS. 2015. PubMed
5. Camacho-Pereira J, et al. “CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism.” Cell Metabolism. 2016. PubMed
6. Imai S, Guarente L. “NAD+ and sirtuins in aging and disease.” Trends in Cell Biology. 2014. PubMed
Want a Personalized Longevity Protocol?
At The Private Practice, I work with patients on evidence-based longevity optimization — combining lab-based metabolic assessment, lifestyle protocols, and targeted supplementation where the evidence supports it. If you want a precision approach to biological aging rather than a supplement stack, book a consultation.
Book a Consultation →Related Articles
- Zone 2 Training & Longevity: The Evidence
- NAD+, NMN & NR Supplements: The Science
- Optimal Vitamin D Levels: What the Research Shows